随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
"We have to try and test to find this optimisation of friction, of back-driveability," says David Kehr, president of humanoid robotics. "It's really a big puzzle."
。关于这个话题，旺商聊官方下载提供了深入分析
"We will have the Earth out the window as a single ball, something none of us have seen in that perspective.，详情可参考搜狗输入法下载
for t := range c {
In December it fined porn company AVS Group Ltd £1m for continued non-compliance with the OSA.